Does estrogen play a role in response to adjuvant bone-targeted therapies?

Journal of Bone Oncology

Volumn 2, Issue 4, 2013, Pages 167-173

  Russell, Kent ^a   Amir, Eitan ^b   Paterson, Alexander ^c   Josse, Robert ^d   Addison, Christina ^e   Kuchuk, Iryna ^a   Clemons, Mark ^a,e  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Adjuvant therapy; Bisphosphonates; Bone targeted therapies; Breast cancer; Estrogen

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GROWTH FACTOR; IBANDRONIC ACID; INTERLEUKIN 6; OCTREOTIDE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; PRASTERONE; PROGESTERONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TAMOXIFEN; TUMOR MARKER; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DISEASE FREE INTERVAL; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; METASTASIS FREE SURVIVAL; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVERALL SURVIVAL; OVULATION INHIBITION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RISK; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 84892813877     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2013.06.001     Document Type: Review

References (85)

1. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026], Breast Cancer Research: BCR 2006;8:R13.
2. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncology 2011:12:631-41.
3. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2008;19:2007-11.
4. Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncology 2008;47:740-6. (Pubitemid 351878444)
5. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. The New England Journal of Medicine 2011;365:1396-405.
6. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncology 2012;13: 734-42.
7. Mobus V, Thomssen C, Harbeck N, Untch M, Jackisch C, IJ D, et al. GAIN (German Adjuvant Intergroup Node Positive) study: a phase III-muliticenter trial to compare dose dense, dose intense etc. (iddETC) vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer-1st interim analysis. CTRC-AACR (ed.) San Antonio breast cancer symposium. San Antonio, TX.
8. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncology 2004;43:650-6. (Pubitemid 39563937)
9. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiologic Reviews 1993;15:48-65. (Pubitemid 23269070)
10. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. The Lancet Oncology 2001;2:133-40. (Pubitemid 33585924)
11. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002;360: 187-95.
12. Stuebe AM, Willett WC, Xue F, Michels KB. Lactation and incidence of premenopausal breast cancer: a longitudinal study. Archives of Internal Medicine 2009;169:1364-71.
13. Zheng T, Holford TR, Mayne ST, Owens PH, Zhang Y, Zhang B, et al. Lactation and breast cancer risk: a case-control study in Connecticut. British Journal of Cancer 2001;84:1472-6. (Pubitemid 32579338)
14. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. (Pubitemid 36999703)
15. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. The New England Journal of Medicine 2009;360:573-87.
16. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
17. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. The New England Journal of Medicine 2007:356:1670-4. (Pubitemid 46631679)
18. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute 2003;95:1218-26. (Pubitemid 37069552)
19. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. British Journal of Cancer 2004;90:153-9. (Pubitemid 38174955)
20. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18:169-76.
21. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. Journal of the National Cancer Institute 2004;96: 1856-65. (Pubitemid 40081323)
22. Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001;19:3111-6. (Pubitemid 32565449)
23. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. Journal of the National Cancer Institute 2011;103:562-70.
24. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 2002;94:606-16. (Pubitemid 34498648)
25. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrine Reviews 2000;21:115-37. (Pubitemid 32275592)
26. Riggs BL, Khosla S, Melton 3rd LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews 2002;23:279-302. (Pubitemid 34651948)
27. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003:423:337-42. (Pubitemid 40852708)
28. Niewoehner C. Endocrine Pathophysiology. Second ed. Raleigh: Hayes Barton Press; 2004.
29. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76. (Pubitemid 28180851)
30. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142: 5050-5. (Pubitemid 33131929)
31. Lacey DL, Tan HL, Lu J, Kaufrnan S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. The American Journal of Pathology 2000:157:435-48. (Pubitemid 30626907)
32. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140:4367-70. (Pubitemid 30647136)
33. Saika M, Inoue D, Kido S, Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001;142:2205-12. (Pubitemid 32473073)
34. Roodman GD. Mechanisms of bone metastasis. The New England Journal of Medicine 2004;350:1655-64.
35. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochemical and Biophysical Research Communications 2005;328:679-87. (Pubitemid 40208305)
36. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. The Journal of Clinical Investigation 1996;97:2692-6. (Pubitemid 26197084)
37. Russell RG. Bisphosphonates: from bench to bedside. Annals of the New York Academy of Sciences 2006:1068:367-401. (Pubitemid 43824169)
38. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nature Medicine 1996;2:1132-6.
39. Hughes DE, Wright KR, Uy HL Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 1995;10:1478-87.
40. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora 2nd AC. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. The American Journal of Medicine 1996;101:488-501. (Pubitemid 126335969)
41. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. The New England Journal of Medicine 1995:333: 1437-43.
42. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Metaanalyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Reviews 2002;23:508-16. (Pubitemid 34925644)
43. Chesnut 3rd CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. The American Journal of Medicine 1995;99:144-52.
44. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010;28:3582-90.
45. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. British Journal of Cancer 2010;102:799-802.
46. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010;28:3577-81.
47. Lipton A. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treatment Reviews 2008;34 (Suppl. 1):S25-30.
48. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treatment Reviews 2008;34: 453-75.
49. Neville-Webbe HL, Holen I, Coleman RE. The anti-tumour activity of bisphosphonates. Cancer Treatment Reviews 2002;28:305-19. (Pubitemid 36054539)
50. Neville-Webbe HL Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. European Journal of Cancer 2010;46:1211-22.
51. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. American Journal of Clinical Oncology 2002;25:S3-9. (Pubitemid 35453651)
52. Hall DG, Stoica G. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 1994;9:221-30. (Pubitemid 24041567)
53. Krempien B, Wingen F, Eichmann T, Muller M, Schmahl D. Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypro-pane- 1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology 1988;45:41-6. (Pubitemid 18017307)
54. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Seminars in Oncology 2001:28:35-44. (Pubitemid 32494623)
55. Padalecki SS, Guise TA. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Research: BCR 2002;4:35-41. (Pubitemid 34097555)
56. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research 1995;55:3551-7.
57. Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. International Journal of Cancer Journal International du Cancer 1998;77:279-85. (Pubitemid 28287982)
58. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000;88:2979-88. (Pubitemid 30413180)
59. Hortobagyi GN, Theriault RL Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. The New England Journal of Medicine 1996;335:1785-91. (Pubitemid 26412396)
60. Kohno N, Aogi K Minami H, Nakamura S, Asaga T, lino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2005;23:3314-21.
61. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1999;17: 846-54. (Pubitemid 29109314)
62. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. Journal of the National Cancer Institute 2012;104:1059-67.
63. Clemons M, Russell K, Costa L Addison CL. Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated? Breast Cancer Research and Treatment 2012;134:453-7.
64. Gregory W, Marshall H, Bell R, Cameron D, Coleman R. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. 2012
65. Coleman R, EJ. R, HC. M, C. W, JE. B, F. G, et al. Vitamin D, but not bone turnover markers, predicty relapse in women with early breast cancer: an AZURE translational study: San Antonio Breast Cancer Symposium. San Antonio; 2012.
66. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. British Journal of Cancer 2001;84:1126-34. (Pubitemid 32448513)
67. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. International Journal of Cancer 1999;83:263-9. (Pubitemid 29449107)
68. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biology 2006;27:92-103.
69. Rinaldi S, Dechaud H, Biessy C, Morin-Raverot V, Toniolo P, Zeleniuch-Jacquotte A, et al. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention: a publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2001;10:757-65. (Pubitemid 32695155)
70. Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement of estradiol: an endocrine society position statement. The Journal of Clinical Endocrinology and Metabolism; 2013;98:1376-1387.
71. Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ. Limitations of direct estradiol and testosterone immunoassay kits. Steroids 2003;68: 1173-8. (Pubitemid 37476355)
72. Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Research: BCR 2005;7:1-4. (Pubitemid 40214529)
73. Ravn P, Hetland ML, Overgaard K, Christiansen C. Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy X-ray absorptiometry. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 1994;9:1975-80. (Pubitemid 24363155)
74. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Stages of Reproductive Aging Workshop (STRAW). Journal of Women's Health & Gender-based Medicine 2001;10:843-8. (Pubitemid 33138765)
75. Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, DiMunno O, et al. Determinants of bone turnover markers in healthy premenopausal women. Calcified Tissue International 2008;82:341-7.
76. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, et al. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Research and Treatment 2013;137: 631-6.
77. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15:32-8.
78. Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, et al. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011;29:3605-10.
79. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Clinical Orthopaedics and Related Research 2003:S138-47. (Pubitemid 37323331)
80. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. The Prostate 2006;66:503-13.
81. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 2009;24:561-74.
82. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008;42: 623-30.
83. Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 1992;7: 1307-11. (Pubitemid 23000971)
84. Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 1999;14:1622-7. (Pubitemid 29416690)
85. Russell K, Clemons M, Costa L, Addison CL Adjuvant bisphosphonate treatment for breast cancer: where are we heading and can the pre-clinical literature help us get there? Journal of Bone Oncology 2012;1:12-7.